Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Alan Menter, Stephen K. Tyring, Kenneth B. Gordon et al. · Journal of the American Academy of Dermatology · 2007 · 869 citations

Autoimmune Disease, Systemic Treatment, Severe Psoriasis +7

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 789 citations

Oncology, Clinical Translation, Originator Infliximab +10

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

J.‐H. Saurat, G Stingl, Louis Dubertret et al. · British Journal of Dermatology · 2007 · 719 citations

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Bente Glintborg, Inge Juul Sørensen, Anne Gitte Loft et al. · Annals of the Rheumatic Diseases · 2017 · 245 citations

The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis

C.E.M. Griffiths, Diamant Thaçi, Sascha Gerdes et al. · British Journal of Dermatology · 2017 · 181 citations · Full text